SkinBioTherapeutics (SBTX) AI Stock Analysis

• Market Cap: £46.60M
• Dividend Yield: N/A
• Average Volume (3M): 1.58M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.05
• Revenue Growth: 1557.07%
• EPS Growth: 24.70%
• Country: UK
• Employees: 15
• Sector: Healthcare
• Sector Strength: 72
• Industry: Biotechnology
• EPS (TTM): -0.01
• Shares Outstanding: 232,975,390
• 10 Day Avg. Volume: 2,356,797
• 30 Day Avg. Volume: 1,584,709
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 318.19
• Price to Cash Flow (P/CF): -18.80
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

SkinBioTherapeutics demonstrates potential growth through recent revenue increases and strategic acquisitions. However, significant financial challenges persist, with ongoing net losses and cash flow issues. Positive technical indicators and corporate events provide some optimism, but valuation concerns due to a negative P/E ratio impact the overall score.

SkinBioTherapeutics Business Overview & Revenue Model

Company Description

SkinBioTherapeutics (SBTX) is a life sciences company based in the United Kingdom, specializing in the development of technology derived from the human microbiome for the treatment and prevention of skin conditions. The company focuses on utilizing its proprietary SkinBiotix technology platform to create products that enhance skin health by harnessing the beneficial properties of specific probiotic bacteria.

How the Company Makes Money

SkinBioTherapeutics generates revenue through the commercialization of its SkinBiotix technology, which includes licensing agreements with commercial partners in the skincare and dermatology sectors. The company collaborates with these partners to develop and market skincare products that incorporate its technology, earning revenue from upfront payments, milestone payments, and royalties on product sales. Additionally, SkinBioTherapeutics may engage in direct product sales or collaborations with research institutions and other companies to explore new applications of its technology, further contributing to its earnings.

SkinBioTherapeutics Financial Statement Overview

Summary

SkinBioTherapeutics shows potential with revenue growth, but substantial net losses and negative cash flows highlight ongoing financial challenges. The company maintains low debt levels but faces declining equity and cash burn, indicating a need for improved cost management and operational efficiency for financial sustainability.

Income Statement

The company has shown significant revenue growth, increasing from zero in previous years to £1.2 million in 2024. However, the gross profit margin stands at 56.5%, indicating some level of cost control. Despite this, the net profit margin is negative due to high operating expenses, resulting in a substantial net loss. EBIT and EBITDA margins are also negative, reflecting ongoing operational challenges.

Balance Sheet

The balance sheet presents a mixed picture. The debt-to-equity ratio is low at 0.28, indicating limited leverage. However, stockholders' equity has been decreasing over recent years, which is concerning. The equity ratio is 56.9%, suggesting moderate reliance on equity financing. Overall, the company's financial stability shows risk due to declining equity.

Cash Flow

Operating cash flow remains negative, though financing activities have provided cash inflows. The free cash flow is negative, indicating cash burn. The operating cash flow to net income ratio is around 0.95, showing that operational cash flows are still insufficient to cover losses. The company's cash position has been bolstered by financing activities, which is unsustainable long-term.

Breakdown
TTM	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement		Total Revenue
161.65K	1.21M	132.06K	74.76K	0.00	0.00
	Gross Profit
73.83K	683.04K	85.19K	15.91K	-5.05K	-5.10K
	EBIT
-3.03M	-2.91M	-3.00M	-2.98M	-1.49M	-1.62M
	EBITDA
-2.98M	-2.72M	-2.96M	-2.95M	-1.49M	-1.61M
	Net Income Common Stockholders
-2.88M	-2.88M	-2.84M	-2.79M	-1.43M	-1.50M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
2.52M	800.90K	1.31M	1.80M	4.61M	2.16M
	Total Assets
3.05M	5.22M	2.59M	3.08M	5.73M	2.77M
	Total Debt
0.00	818.74K	100.65K	127.86K	139.85K	0.00
	Net Debt
-2.52M	17.84K	-1.21M	-1.68M	-4.47M	-2.16M
	Total Liabilities
103.39K	2.25M	599.34K	609.61K	519.67K	304.83K
	Stockholders Equity
2.94M	2.97M	1.99M	2.48M	5.22M	2.47M
Cash Flow		Free Cash Flow
-3.17M	-2.92M	-2.81M	-2.77M	-1.67M	-965.80K
	Operating Cash Flow
-3.02M	-2.73M	-2.65M	-2.67M	-1.56M	-892.14K
	Investing Cash Flow
-214.57K	-2.30M	-165.28K	-96.81K	-112.31K	-73.67K
	Financing Cash Flow
5.31M	4.51M	2.32M	-35.12K	4.12M	0.00

SkinBioTherapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 20.00
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:SBTX, the sentiment is Positive. The current price of 20 is below the 20-day moving average (MA) of 22.45, below the 50-day MA of 21.47, and above the 200-day MA of 16.03, indicating a neutral trend. The MACD of -0.53 indicates Positive momentum. The RSI at 47.61 is Neutral, neither overbought nor oversold. The STOCH value of 35.24 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:SBTX.

SkinBioTherapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	50 Neutral	$5.51B	2.95	-43.70%	2.78%	16.94%	3.59%
SBTX	47 Neutral	£46.60M	―	-63.28%	―	1557.07%	24.70%
SAR	47 Neutral	£24.70M	―	-87.30%	―	―	71.17%
IXI	41 Neutral	£7.97M	―	-19.15%	―	-13.49%	-69.67%
NFX	38 Underperform	£2.21M	―	-148.31%	―	―	-462.50%

SkinBioTherapeutics Corporate Events

SkinBioTherapeutics Celebrates Successful Launch of Zenakine™ Amid Share Price Concerns

SkinBioTherapeutics announced the successful global launch of Zenakine™ by Croda Beauty at the in-cosmetics Global 2025 meeting, receiving a standing ovation for its technical presentation. Zenakine™ offers benefits such as improved cell longevity, skin regeneration, and anti-aging effects. Despite the positive reception, the company noted an unexplained drop in share price. The management plans to discuss Zenakine™’s attributes and commercialization at an upcoming investor presentation, highlighting its potential impact on the company’s market position and stakeholder interests.

Spark’s Take on GB:SBTX Stock

According to Spark, TipRanks’ AI Analyst, GB:SBTX is a Neutral.

SkinBioTherapeutics presents a mixed outlook. Despite positive market momentum and promising corporate developments, financial challenges due to ongoing losses and negative cash flow remain significant concerns. The stock’s valuation is hindered by a negative P/E ratio, but the potential for market expansion through strategic launches and partnerships offers a positive long-term view.

To see Spark’s full report on GB:SBTX stock, click here.

SkinBioTherapeutics and Croda Unveil Zenakine™ at Global Cosmetics Event

SkinBioTherapeutics announced that Croda plc has launched Zenakine™, a neuroactive ingredient designed to improve skin health by reducing stress effects and enhancing sleep quality, at the in-cosmetics Global exhibition. This launch marks a significant milestone for SkinBioTherapeutics, as Zenakine™ is the first ingredient with clinical measures on sleep benefits, offering a competitive edge in the cosmetics industry with its multifunctional and sustainable formulation options.

Spark’s Take on GB:SBTX Stock

According to Spark, TipRanks’ AI Analyst, GB:SBTX is a Neutral.

SkinBioTherapeutics shows promise with recent revenue growth and strategic acquisitions. However, significant financial challenges remain due to ongoing losses and negative cash flow. The stock’s technical indicators suggest positive momentum, while corporate events highlight potential market expansion. The valuation remains a concern due to the negative P/E ratio.

To see Spark’s full report on GB:SBTX stock, click here.

SkinBioTherapeutics Announces Change in Major Shareholdings

SkinBioTherapeutics PLC has announced a change in its major holdings, with Optibiotix Health plc reducing its voting rights from 9.58% to 8.46%. This adjustment in shareholding reflects a strategic shift and could impact the company’s governance and decision-making processes, potentially influencing its market position and stakeholder interests.

Spark’s Take on GB:SBTX Stock

According to Spark, TipRanks’ AI Analyst, GB:SBTX is a Neutral.

SkinBioTherapeutics shows promise with recent revenue growth and strategic acquisitions. However, significant financial challenges remain due to ongoing losses and negative cash flow. The stock’s technical indicators suggest positive momentum, while corporate events highlight potential market expansion. The valuation remains a concern due to the negative P/E ratio.

To see Spark’s full report on GB:SBTX stock, click here.

SkinBioTherapeutics Announces Warrant Exercise and Share Increase

SkinBioTherapeutics plc announced the exercise of warrants by Macquarie for 1,000,000 ordinary shares at £0.2043 per share, leaving 1,099,244 warrants outstanding. Following this exercise, the company’s total issued shares and voting rights will increase to 232,975,383, impacting shareholder calculations under the Financial Conduct Authority’s rules.

SkinBioTherapeutics Reports Strong Half-Year Growth and Prepares for Major Product Launch

SkinBioTherapeutics has reported significant revenue growth for the half-year ending December 2024, driven by acquisitions and increased sales of its AxisBiotix product. The company completed the integration of Dermatonics and Bio-Tech Solutions, which contributed to its strengthened financial position. The upcoming global launch of its SkinBiotix lysate by Croda is anticipated to further enhance its market presence. The company is focused on expanding its product offerings and enhancing its operational capabilities, positioning itself for future profitability.

SkinBioTherapeutics Expands Share Capital with Warrant Exercise

SkinBioTherapeutics plc announced the exercise of warrants by Macquarie for 250,000 ordinary shares at £0.2043 per share, increasing the company’s total issued shares to 231,975,383. This development reflects the company’s ongoing efforts to strengthen its financial position and expand its market presence, potentially impacting shareholder interests and enhancing its industry positioning.

SkinBioTherapeutics Announces Change in Voting Rights

SkinBioTherapeutics PLC has announced a change in voting rights following an acquisition or disposal by David Campbell Brierwood, who now holds 5.561% of the company’s voting rights, up from a previous 4.1%. This change in voting rights could potentially impact the company’s shareholder dynamics and influence future decision-making processes.

SkinBioTherapeutics Reduces Debt via Warrant Exercise Post Acquisition

SkinBioTherapeutics announced the exercise of warrants by David Brierwood, reducing the company’s debt from £950,000 to £600,000 following their acquisition of Bio-Tech Solutions Limited. The new ordinary shares will be admitted to AIM, adjusting the total issued shares to 231,725,383. CEO Stuart Ashman highlighted the successful integration of Bio-Tech Solutions, which aligns with expectations and will contribute to upcoming financial results.